Recently published open access in the journal Nature Communications*, an invited Comment article first authored by VHIO’s Elena Garralda, sets…
featured news
Blood-based circulating tumor DNA analysis of plasma samples from patients enrolled in the open-label, randomized phase III VOYAGER clinical trial…
VHIO has participated in this project coordinated by INCLIVA, which has made it possible to expand knowledge about this type…
Results of the study FRESCO-2 show a statistically and clinically meaningful benefit with a favorable safety profile in patients with…
Approximately 70% of advanced breast cancers are hormone receptor-positive (HR+)/HER2-negative. Hormone therapies are widely used for the treatment of patients…
In recognition of multidisciplinary integrated cancer care, translational and clinical cancer research of excellence at the Vall d’Hebron University Hospital…
In an invited Viewpoint article recently published open access and ahead of print in the journal Molecular Oncology*, VHIO’s Joan…
Published in The Lancet Oncology results of the multicenter phase II MOUNTAINEER study (1) show that tucatinib plus trastuzumab had…
Advancing precision medicine in lung cancer, several studies (co) led by VHIO investigators have been presented, discussed, and debated at…
Pancreatic cancer accounts for almost as many deaths (466,000) as cases (496,000) because of its poor prognosis. It is the…
